### Contents

#### Highlights of This Issue 5915

**SPECIAL FEATURES**

**CCR Translations**

- **5917** Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy  
  William E. Carson III

- **5920** Toward a Better Understanding of Race and Cancer  
  Otis W. Brawley

**CCR Drug Updates**

- **5923** Pazopanib in Renal Cell Carcinoma  
  James E. Ward and Walter M. Stadler

**Molecular Pathways**

- **5928** Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis  
  Xin Lu and Yibin Kang

- **5936** Targeting RET Receptor Tyrosine Kinase Activation in Cancer  
  John E. Phay and Manisha H. Shah

**Review**

- **5942** Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion  
  Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel

**CCR Focus**

- **5950** Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease  
  Susan E. Bates

- **5951** Translating Clinical Trials into Meaningful Outcomes  
  Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf

- **5964** Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction?  
  Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch

- **5971** Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past  
  Christopher M. Booth

- **5973** Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?  
  Tito Fojo and David R. Parkinson

- **5981** Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small  
  Thomas J. Smith and Bruce E. Hillner

- **5987** The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally  
  William S. Dalton, Daniel M. Sullivan, Timothy J. Yeatman and David A. Fenstermacher

- **5991** The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center  
  Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamerus, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz Jr., Jean G. Ford, Norma Kanarek and Charles M. Rudin

- **5997** Value and Cancer Care: Toward an Equitable Future  
  Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock

---

The Journal of Clinical and Translational Research  
December 15, 2010 • Volume 16 • Number 24

---

Downloaded from clincancerres.aacrjournals.org on April 30, 2017. © 2010 American Association for Cancer Research.
HUMAN CANCER BIOLOGY

6009  IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

6019  Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann

6029  Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

6040  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

IMAGING, DIAGNOSIS, PROGNOSIS

6083  Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

6093  Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

6100  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study

6111  A Combination of Serum Markers for the Early Detection of Colorectal Cancer
Norbert Wild, Herbert Andres, Wolfgang Rollinger, Friedemann Krause, Peter Dilba, Michael Tacke and Johann Karl

CANCER THERAPY: PRECLINICAL

6122  CDS+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udalı Ş. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

CANCER THERAPY: CLINICAL

6132  Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAh-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

LETTERS TO THE EDITOR

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences? Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth and Nicholas Turner

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, I-Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes and Christine B. Ambrosone
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133+ glioblastoma stem-like cell line GBMJ1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.